Modified release formulations of memantine oral dosage forms

Details Modified release formulations of memantine oral dosage forms Modified release formulations of memantine oral dosage forms

2005-06-16

2011-10-18

Fetterolf, Brandon (Department: 1628)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

C514S766000

Reexamination Certificate

active

08039009

ABSTRACT:
The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

REFERENCES:
patent: 4122193 (1978-10-01), Scherm et al.
patent: 4273774 (1981-06-01), Scherm
patent: 5007790 (1991-04-01), Shell
patent: 5061703 (1991-10-01), Bormann et al.
patent: 5334618 (1994-08-01), Lipton
patent: 5382601 (1995-01-01), Nürnberg et al.
patent: 5506231 (1996-04-01), Lipton
patent: 5582837 (1996-12-01), Shell
patent: 5614560 (1997-03-01), Lipton
patent: 5972389 (1999-10-01), Shell et al.
patent: 6034134 (2000-03-01), Gold et al.
patent: 6071966 (2000-06-01), Gold et al.
patent: 6194000 (2001-02-01), Smith et al.
patent: 6413556 (2002-07-01), Bathurst et al.
patent: 6444702 (2002-09-01), Wang et al.
patent: 6479553 (2002-11-01), McCarthy
patent: 2004/0102525 (2004-05-01), Kozachuk
patent: 2005/0245617 (2005-11-01), Meyerson et al.
patent: 2006/0002999 (2006-01-01), Yang et al.
patent: 2006/0142398 (2006-06-01), Went et al.
patent: 2007/0065512 (2007-03-01), Dedhiya et al.
patent: 2009/0247644 (2009-10-01), Dedhiya et al.
patent: 0284849 (1988-10-01), None
patent: WO-96/26718 (1996-09-01), None
patent: WO-98/55107 (1998-12-01), None
patent: WO 02/45710 (2002-06-01), None
Hartmann et al ‘Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy’ International Clinical Psychopharmacology, 18(2), p. 81-85, 2003.
Tariot et al ‘Memantine Treatment in Patients with Moderate to Severe Alzheimer's Disease Already Receiving Donepezil’ JAMA, 291(3), p. 317-324, Jan. 2004.
International Search Report mailed on Oct. 6, 2005 for corresponding Application No. PCT/US2005/021260.
Parsons et al.,Neuropharmacology; 38(6):735-767 (1999).
FDA Guidelines (Dissolution Testing of Immediate Release Solid Oral Dosage Forms, issued, Section IV-A) (Aug. 1997).
Guidance for Industry, “Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations”, Food and Drug Administration, CDER, p. 17, (Sep. 1997).
Guidance for Industry, “Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations,” Food and Drug Administration, CDER, p. 4 (Sep. 1997).
Guidance for Industry,: “Modified Release Solid Oral Dosage Forms,” Food and Drug Administration, CDER, p. 6, (Sep. 1997).
Multisource Pharmaceutical Products: Guidelines on Registration Requirements to establish Interchangeability, Quality Assurance and Safety: Medicines, Essential Drugs and Medicines Policy, World Health Organization, 1211 Geneva 27, Switzerland, pp. 11-12 (2004).
U.S. Pharmacopoeia and National Formulary, USP XXIV / NF 19, Chapter 1088, pp. 2051-2056 (2000).
U.S. Pharmacopoeia and National Formulary, USP XXIV / NF 19, Chapter 711, pp. 1941-1943 (2000).
Reisberg Barry et al: “Memantine in moderate-to-severe Alzheimer's disease.” The New England Jouunal of Medicine. Apr. 3, 2003, vol. 348, No. 14, Apr. 3, 2003, pp. 1333-1341, XP009054230, ISSN: 1533-4406, abstract.
Suzuki Rie et al: “Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy”, PAIN, vol. 91, No. 1-2, Mar. 2001, pp. 101-109, XP002346013, ISSN: 0304-3959, abstract, p. 107, col. 2, paragraph 2 & p. 108, col. 1, paragraph 3.
First Action Interview Pilot Program Pre-Interview Communication for U.S. Appl. No. 11/424,024 mailed Dec. 17, 2009.
Response to Pre-Interview Communication for U.S. Appl. No. 11/424,024, filed Jan. 6, 2010.
Interview Summary, date of interview Jan. 22, 2010 for U.S. Appl. No. 11/424,024 mailed Feb. 1, 2010.
First Action Interview Office Action Summary for U.S. Appl. No. 11/424,024 mailed Feb. 1, 2010.
Interview Summary, date of interview Feb. 16, 2010 for U.S. Appl. No. 11/424,024 mailed Feb. 24, 2010.
Response to First Action Interview Office Action Summary for U.S. Appl. No. 11/424,024, filed Feb. 16, 2010.
Final Office Action for U.S. Appl. No. 11/424,024 mailed Jun. 3, 2010.
Response to Final Office Action for U.S. Appl. No. 11/424,024, filed Aug. 18, 2010.
International Search Report mailed on Oct. 19, 2006 for PCT/US2006/022841 corresponding to U.S. Appl. No. 11/424,024.

Affiliated with

Also associated with

Rating

Modified release formulations of memantine oral dosage forms does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified release formulations of memantine oral dosage forms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified release formulations of memantine oral dosage forms will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4260636